Tokushima University / Educator and Researcher Directory --- Yoneda, Shintaro

Personal Web Page

https://researchmap.jp/no515drnk (researchmap)

https://orcid.org/0009-0005-0390-2848 (ORCID)

Field of Study

○

Subject of Study

○	(drug delivery system, liposomes, 脳梗塞, 微弱電流処理)

Book / Paper

(See https://researchmap.jp/no515drnk (researchmap) for Published Book / Papers / Presentations.)

Academic Paper (Judged Full Paper):

1.	Yamasaki Minori, Shintaro Yoneda, Maoka Takashi and Kentaro Kogure : Marked enhancement of synergistic antioxidative activity of astaxanthin and curcumin by co-encapsulation in a liposomal formulation, Journal of Clinical Biochemistry and Nutrition, 2025.
2.	Shintaro Yoneda and Kentaro Kogure : Development of Low-Density Lipoprotein Receptor-Targeted Liposomes for Enhanced Accumulation in Ischemia/Reperfusion Environment, Biological & Pharmaceutical Bulletin, 48, 7, 1008-1015, 2025. (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b25-00118 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-105010339099 (DOI: 10.1248/bpb.b25-00118, Elsevier: Scopus)
3.	Yuika Seto, Alam S. M. Tafsirul Tapu, Natsuho Kugisaki, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : Liposomal formulation co-encapsulating α-tocopheryl succinate and α-tocopherol ameliorates high-fat diet-induced obesity, Journal of Pharmaceutical Sciences, 114, 5, 103724, 2025. (Summary) Lipid accumulation inhibition is a pivotal focus for anti-obesity drugs. α-Tocopheryl succinate (TS) is a derivative of α-tocopherol (T) that inhibits lipid accumulation, making it a propitious candidate for an anti-obesity agent. However, cytotoxicity of TS limits its application. Reactive oxygen species produced by TS are responsible for the cytotoxicity, which can be mitigated by T. Herein, we evaluated the effect of a liposomal formulation co-encapsulating TS and T (TS/T-lipo) on obesity. We prepared TS/T-lipo and evaluated the resultant cytotoxicity and lipid accumulation inhibition effect in vitro. TS/T-lipo showed a significant inhibitory effect on lipid accumulation without cytotoxicity. The inhibitory effect on lipid accumulation is likely due to upregulation of Uncoupling Protein 1, which causes lipid consumption. Moreover, we evaluated the effect of TS/T-lipo on a high-fat diet-induced obese mouse model and found that body weight significantly decreased in the TS/T-lipo group without elevation of liver toxicity or blood glucose levels. Additionally, increased glycerol serum levels are suggestive of increased lipolysis upon treatment with TS/T-lipo. Histological analysis supports inhibition of lipid accumulation by treatment with TS/T-lipo. Taken together, this evidence demonstrates that co-administration of TS/T can reduce cytotoxicity and may be a promising candidate for an anti-obesity drug. (Keyword) Lipid accumulation / Liposome / Obesity / α-Tocopherol / α-Tocopheryl succinate (Link to Publication Site) ● Publication site (DOI): 10.1016/j.xphs.2025.103724 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 40089019 ● Summary page in Scopus @ Elsevier: 2-s2.0-105000351646 (DOI: 10.1016/j.xphs.2025.103724, PubMed: 40089019, Elsevier: Scopus)
4.	Hibiki Yoshida, Rio Yamaguchi, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : Intradermal Delivery of a Liposomal Formulation Encapsulating Amphiphilic Ascorbic Acid by Iontophoresis for Promotion of Collagen Synthesis, Journal of Drug Delivery Science and Technology, 103, 106438, 2025. (Tokushima University Institutional Repository) ● Metadata: 2012351 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.jddst.2024.106438 (Link to Search Site for Scientific Articles) ● Summary page in Scopus @ Elsevier: 2-s2.0-85210301454 (Tokushima University Institutional Repository: 2012351, DOI: 10.1016/j.jddst.2024.106438, Elsevier: Scopus)
5.	Shintaro Yoneda, Tatsuya Fukuta, Mizune Ohzono and Kentaro Kogure : Enhancement of cerebroprotective effects of lipid nanoparticles encapsulating FK506 on cerebral ischemia/reperfusion injury by particle size regulation, Biochemical and Biophysical Research Communications, 611, 53-59, 2022. (Summary) Delivery of cerebroprotective agents using liposomes has been demonstrated to be useful for treating cerebral ischemia/reperfusion (I/R) injury. We previously reported that intravenous administration of liposomes with diameters of 100 nm showed higher accumulation in the I/R region compared with larger liposomes (>200 nm) by passage through the disintegrated blood-brain barrier, suggesting a size-dependence for liposome-mediated drug delivery. Based on these findings, we hypothesized that regulation of liposomal particle size (<100 nm) may enhance the therapeutic efficacy of encapsulated drugs on cerebral I/R injury. Herein, we prepared lipid nanoparticles (LNP) with particle sizes <100 nm by the microfluidics method and compared their therapeutic potential with LNP exhibiting sizes >100 nm in cerebral I/R model rats. Intravenously administered smaller LNP (ca. 60 nm) exhibited wider accumulation and diffusivity in the brain parenchyma of the I/R region compared with larger LNP (>100 nm). Importantly, treatment with LNP encapsulating the cerebroprotective agent FK506 (FK-LNP) with particle sizes <100 nm showed greater cerebroprotective effects than FK-LNP with sizes >100 nm, and also significantly ameliorated brain injury. These results suggest that particle size regulation of LNP to sizes <100 nm can enhance the therapeutic effect of encapsulated drugs for treatment of cerebral I/R injury, and that FK-LNP could be a promising cerebroprotective agent. (Keyword) Animals / Brain Ischemia / Liposomes / Nanoparticles / Neuroprotective Agents / Particle Size / Rats / Rats, Wistar / Reperfusion Injury / Tacrolimus (Tokushima University Institutional Repository) ● Metadata: 2010079 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.bbrc.2022.04.080 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35477093 ● Search Scopus @ Elsevier (PMID): 35477093 ● Search Scopus @ Elsevier (DOI): 10.1016/j.bbrc.2022.04.080 (Tokushima University Institutional Repository: 2010079, DOI: 10.1016/j.bbrc.2022.04.080, PubMed: 35477093)
6.	Anowara Khatun, Mahadi Hasan, Mahran Abd Mohamed El-Emam, Tatsuya Fukuta, Miyuki Mimura, Riho Tashima, Shintaro Yoneda, Shintaroh Yoshimi and Kentaro Kogure : Effective Anticancer Therapy by Combination of Nanoparticles Encapsulating Chemotherapeutic Agents and Weak Electric Current, Biological & Pharmaceutical Bulletin, 45, 2, 194-199, 2022. (Summary) Delivery of medicines using nanoparticles via the enhanced permeability and retention (EPR) effect is a common strategy for anticancer chemotherapy. However, the extensive heterogeneity of tumors affects the applicability of the EPR effect, which needs to overcome for effective anticancer therapy. Previously, we succeeded in the noninvasive transdermal delivery of nanoparticles by weak electric current (WEC) and confirmed that WEC regulates the intercellular junctions in the skin by activating cell signaling pathways (J. Biol. Chem., 289, 2014, Hama et al.). In this study, we applied WEC to tumors and investigated the EPR effect with polyethylene glycol (PEG)-modified doxorubicin (DOX) encapsulated nanoparticles (DOX-NP) administered via intravenous injection into melanoma-bearing mice. The application of WEC resulted in a 2.3-fold higher intratumor accumulation of nanoparticles. WEC decreased the amount of connexin 43 in tumors while increasing its phosphorylation; therefore, the enhancing of intratumor delivery of DOX-NP is likely due to the opening of gap junctions. Furthermore, WEC combined with DOX-NP induced a significant suppression of tumor growth, which was stronger than with DOX-NP alone. In addition, WEC alone showed tumor growth inhibition, although it was not significant compared with non-treated group. These results are the first to demonstrate that effective anticancer therapy by combination of nanoparticles encapsulating chemotherapeutic agents and WEC. (Keyword) Animals / Antineoplastic Agents / Doxorubicin / Drug Delivery Systems / Electrochemical Techniques / male / Melanoma / Mice / Mice, Inbred C57BL / nanoparticles / Neoplasms, Experimental / Xenograft Model Antitumor Assays (Tokushima University Institutional Repository) ● Metadata: 2010077 (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b21-00714 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35110506 ● Summary page in Scopus @ Elsevier: 2-s2.0-85123844154 (Tokushima University Institutional Repository: 2010077, DOI: 10.1248/bpb.b21-00714, PubMed: 35110506, Elsevier: Scopus)
7.	Yuma Hirata, Riho Tashima, Naoto Mitsuhashi, Shintaro Yoneda, Mizune Ohzono, Eiji Majima, Tatsuya Fukuta and Kentaro Kogure : A simple, fast, and orientation-controllable technology for preparing antibody-modified liposomes, International Journal of Pharmaceutics, 607, 25, 120966, 2021. (Summary) Modification with antibodies is a useful strategy for the delivery of nanoparticles to target cells. However, the complexity of the required chemical modifications makes them time-consuming and low efficiency, and the orientation of the antibody is challenging to control. To develop a simple, fast, effective, and orientation-controllable technology, we employed staphylococcal protein A, which can bind to the Fc region of antibodies, as a tool for conjugating antibodies to nanoparticles. Specifically, we modified the C-domain dimer of protein A to contain a lysine cluster to create a molecule, DPACK, that would electrostatically bind to anionic liposomes. Using this protein, antibody-modified liposomes can be prepared in 35 min with two steps: (1) interaction of DPACK with liposomes and (2) interaction of an antibody with DPACK-modified liposomes. Binding efficiencies of DPACK with liposomes and IgG with DPACK-modified liposomes were 75% and 72-84%, respectively. Uptake of liposomes modified with anti-epidermal growth factor receptor (EGFR) antibodies via DPACK by EGFR-expressing cancer cells was significantly higher than that of unmodified liposomes, and the liposomes accumulated in tumors and colocalized with EGFR. This simple, fast, effective and orientation-controllable technology for preparing antibody-modified liposomes will be useful for active targeting drug delivery. (Tokushima University Institutional Repository) ● Metadata: 2009066 (Link to Publication Site) ● Publication site (DOI): 10.1016/j.ijpharm.2021.120966 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34352337 ● Summary page in Scopus @ Elsevier: 2-s2.0-85112221934 (Tokushima University Institutional Repository: 2009066, DOI: 10.1016/j.ijpharm.2021.120966, PubMed: 34352337, Elsevier: Scopus)
8.	Tatsuya Fukuta, Natsu Nakatani, Shintaro Yoneda and Kentaro Kogure : Weak electric current treatment to artificially enhance vascular permeability in embryonated chicken eggs, Biological & Pharmaceutical Bulletin, 43, 11, 1729-1734, 2020. (Summary) Technologies that overcome the barrier presented by vascular endothelial cells are needed to facilitate targeted delivery of drugs into tissue parenchyma by intravenous administration. We previously reported that weak electric current treatment (ET: 0.3-0.5 mA/cm) applied onto skin tissue in a transdermal drug delivery technique termed iontophoresis induces cleavage of intercellular junctions that results in permeation of macromolecules such as small interfering RNA and cytosine-phosphate-guanine (CpG) oligonucleotide through the intercellular space. Based on these findings, we hypothesized that application of ET to blood vessels could promote cleavage of intercellular junctions that artificially induces increase in vascular permeability to enhance extravasation of drugs from the vessels into target tissue parenchyma. Here we investigated the effect of ET (0.34 mA/cm) on vascular permeability using embryonated chicken eggs, which have blood vessels in the chorioallantoic membrane (CAM), as an animal model. ET onto the CAM of the eggs significantly increased extravasation of intravenously injected calcein (M.W. 622.6), a low molecular weight compound model, and the macromolecule fluorescein isothiocyanate (FITC)-dextran (M.W. 10000). ET-mediated promotion of penetration of FITC-dextran through vascular endothelial cells was also observed in transwell permeability assay using monolayer of human umbilical vein endothelial cells without induction of obvious cellular damage. Confocal microscopy detected remarkable fluorescence derived from injected FITC-dextran in blood vessel walls. These results in embryonated chicken eggs suggest that ET onto blood vessels could artificially enhance vascular permeability to facilitate extravasation of macromolecules from blood vessels. (Keyword) Animals / Capillary Permeability / Chickens / Chorioallantoic Membrane / Dextrans / Electric Stimulation / Endothelium, Vascular / Fluorescein-5-isothiocyanate / Human Umbilical Vein Endothelial Cells / Humans / Injections, Intravenous / Microscopy, Confocal (Tokushima University Institutional Repository) ● Metadata: 2008098 (Link to Publication Site) ● Publication site (DOI): 10.1248/bpb.b20-00423 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33132318 ● Summary page in Scopus @ Elsevier: 2-s2.0-85095385288 (Tokushima University Institutional Repository: 2008098, DOI: 10.1248/bpb.b20-00423, PubMed: 33132318, Elsevier: Scopus)

Proceeding of Domestic Conference:

1.	Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : 虚血/再灌流領域血管内皮に対するリポソーム標的化に関する検討, 日本薬学会第145年会, Mar. 2025.
2.	S Alam Tafsirul M Tapu, Kinari Hayashi, Michiyasu Nakao, Shigeki Sano, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : Vitamin E derivative attenuates obesity, 第34回ビタミンE研究会, Jan. 2025.
3.	Michiko Kiyofuji, Ray Manobendro Nath, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : ビタミンEコハク酸によるアポトーシス誘導機構のがん・正常細胞での比較, 第34回ビタミンE研究会, Jan. 2025.
4.	S Alam Tafsirul M Tapu, Kinari Hayashi, Shintaro Yoneda, Michiyasu Nakao, Naoshi Yamazaki, Shigeki Sano and Kentaro Kogure : Anti-obesity effect of ether type tocopherol derivative on obese mice, BioMedical Forum 2025, Dec. 2024.
5.	Zhiqiang Zhou, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : 薬物封入リポソームのイオントフォレシスによる薬物徐放性の検討, BioMedical Forum 2025, Dec. 2024.
6.	Kentaro Kogure, Minori Yamasaki, Shintaro Yoneda and Naoshi Yamazaki : リポソーム脂質膜中における抗酸化物質の相互作用に基づく抗酸化活性向上機構の解明, 膜シンポジウム2024, Nov. 2024.
7.	Shintaro Yoneda, Naoshi Yamazaki, Masaya Denda, Akira Otaka and Kentaro Kogure : 脳虚血/再灌流後の脳血管内皮細胞周辺環境変化を利用した薬物送達に関する検討, 膜シンポジウム2024, Nov. 2024.
8.	Airi Yamamoto, Chiho Ohtsuka, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : イオントフォレシス処理による皮膚バリア機能関連因子への影響, 第63回日本薬学会・日本薬剤師会・日本病院薬剤師会, Nov. 2024.
9.	Taku Nakayama, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : 微弱電流を用いるイオントフォレシスの細胞生理への影響, 第63回日本薬学会・日本薬剤師会・日本病院薬剤師会, Nov. 2024.
10.	Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : 虚血/再灌流領域に対する能動的薬物送達を目的とした標的分子探索, 第63回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2024.
11.	YAMAGUCHI Rio, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : コラーゲン合成の誘導を⽬的としたビタミンC の⾮侵襲的⽪内送達, 遺伝⼦・デリバリー研究会熊本カンファレンス2024, Oct. 2024.
12.	YAMAGUCHI Rio, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : コラーゲン合成の誘導を目的としたビタミンCの非侵襲的皮内送達, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
13.	S Alam Tafsirul M Tapu, Kinari Hayashi, Michiyasu Nakao, Shigeki Sano, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : Effects of ether type vitamin E derivative in high-fat diet induced obese mice, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
14.	Yusuke Yoshimura, Shinya Inoue, Mahadi Hasan, Tatsuya Fukuta, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : イオントフォレシスによる肝臓局所的な核酸医薬の送達, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
15.	YAMASAKI Minori, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : 脂質膜中での分子間相互作用による抗酸化活性向上リポソームの開発, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
16.	KIYOFUJI Michiko, MANOBENDRO NATH RAY, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : がん細胞に特異的なビタミンEコハク酸によるアポトーシス誘導機構の検討, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
17.	MOTOMURA Fu, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : 妊娠高血圧症候群治療を目指したビタミンEコハク酸による組織・細胞内酸化ストレス誘導の検討, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
18.	Shinya Inoue, Mahadi Hasan, Tatsuya Fukuta, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : イオントフォレシスを用いた肝臓表面からのsiRNA送達による疾患治療, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
19.	SUMIYA Yumi, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : 抗腫瘍医薬品を組み合わせたイオントフォレシスによる皮内送達の検討, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
20.	KUGISAKI Natsuho, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : ビタミンEコハク酸による脂肪蓄積抑制効果のメカニズムの検討, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
21.	URANISHI Mari, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : サルコペニア治療を目指したイオントフォレシスによる骨格筋への核酸送達, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
22.	Kinari Hayashi, TAPU TAFSIRUL M S ALAM, Shintaro Yoneda, Michiyasu Nakao, Naoshi Yamazaki, Shigeki Sano and Kentaro Kogure : 構造安定性を向上させたトコフェロールエーテル誘導体の脂肪蓄積抑制効果とそのメカニズム, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
23.	Benjamin Chee Tam Keen, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : アスタキサンチンとのリポソーム共封入によるビタミンEコハク酸の生物活性制御の検討, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
24.	Taku Nakayama, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : イオントフォレシス時の微弱電流が細胞生理に及ぼす影響の検討, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
25.	KOMATSU Aya, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : 非接触型イオントフォレシスによるヒアルロン酸の皮内送達, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
26.	YAMAMOTO Mizuki, 阿部洋, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : イオントフォレシスによる効率的なmRNAワクチンシステムの確立, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
27.	Airi Yamamoto, Chiho Ohtsuka, Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : 皮膚バリア機能関連因子に対してイオントフォレシスが及ぼす影響, 第45回生体膜と薬物の相互作用シンポジウム, Oct. 2024.
28.	Shintaro Yoneda, Naoshi Yamazaki and Kentaro Kogure : 脳虚血/再灌流領域の特性を利用した薬物送達法開発の検討, 第45回生体膜と薬物の相互作用シンポジウム, Aug. 2024.
29.	Kentaro Kogure, Shintaro Yoneda and Naoshi Yamazaki : 微弱電流による高分子物質の細胞質送達, 日本膜学会第46年会, Jun. 2024.
30.	Kentaro Kogure, HARUKI Konishi, Shintaro Yoneda and Naoshi Yamazaki : 非接触型イオントフォレシスによる皮内薬物送達, 日本薬剤学会第39年会, May 2024.
31.	YAMASAKI Minori, Shintaro Yoneda and Kentaro Kogure : 分子間相互作用を利用した抗酸化活性向上リポソーム製剤の開発, 日本薬剤学会第39年会, May 2024.
32.	Shintaro Yoneda and Kentaro Kogure : 脳虚血/再灌流環境を利用したナノ粒子送達技術の確立, 日本薬剤学会第39年会, May 2024.
33.	Shintaro Yoneda, Tatsuya Fukuta, Mizune Ohzono and Kentaro Kogure : 粒子径制御脂質ナノ粒子の脳虚血再灌流領域への効率的送達, 第44回生体膜と薬物の相互作用シンポジウム, Oct. 2023.
34.	Shintaro Yoneda, Tatsuya Fukuta, Mizune Ohzono and Kentaro Kogure : 脳保護薬FK506封入脂質ナノ粒子の粒子径制御を介した脳虚血/再灌流治療効果の向上, 遺伝子・デリバリー研究会第21回シンポジウム，第20回夏季セミナー, Aug. 2022.
35.	Shintaro Yoneda, Tatsuya Fukuta, Mizune Ohzono and Kentaro Kogure : FK506封入脂質ナノ粒子の粒子径制御による脳虚血/再灌流障害に対する治療効果の向上, 日本薬剤学会第37年会, May 2022.
36.	Shintaro Yoneda, Tatsuya Fukuta, Mizune Ohzono and Kentaro Kogure : 粒子径制御FK506内封脂質ナノ粒子の構築と脳梗塞部位への送達効率の向上, 第60回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2021.
37.	Shintaro Yoneda, Tatsuya Fukuta and Kentaro Kogure : 脳虚血/再灌流障害の治療を目指した粒子径制御リポソーム化FK506の構築, 日本薬剤学会第36年会, May 2021.
38.	Shintaro Yoneda, Tatsuya Fukuta and Kentaro Kogure : 脳虚血/再灌流部位へのリポソーム集積性に及ぼす粒子径の影響, 第36回日本DDS学会学術集会, Aug. 2020.
39.	Shintaro Yoneda, 中谷奈津, Tatsuya Fukuta and Kentaro Kogure : 脳への微弱電流処理による脳血管透過制御を目指した検討, 第58回日本薬学会・日本薬剤師会・日本病院薬剤師会中国四国支部学術大会, Nov. 2019.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

再灌流脳障害領域特異的薬物送達と中枢神経系再生を組み合わせた複合的脳梗塞治療法 (Project/Area Number: 24K23056 )
Search by Researcher Number (31001513)

Assistant Professor : Yoneda, Shintaro

Research

Personal Web Page

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Proceeding of Domestic Conference:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)